Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders.
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders.
复制标题
为社区制定的遗传性出血性疾病国家研究蓝图奠定基础:超罕见遗传性出血性疾病的研究重点。
DOI:
10.1080/17474086.2023.2175661
复制
发表时间:
2023
影响因子:
2.8
通讯作者:
Peltier,Sky
中科院分区:
文献类型:
--
作者:
Nugent,Diane;Acharya,SuchitraS;Baumann,KimberlyJ;Bedrosian,Camille;Bialas,Rebecca;Brown,Kai;Corzo,Deya;Haidar,Amar;Hayward,CatherinePM;Marks,Peter;Menegatti,Marzia;Miller,MargaretE;Nammacher,Kate;Palla,Roberta;Peltier,Sky
BackgroundUltra-rare inherited bleeding disorders (BDs) present important challenges for generating a strong evidence foundation for optimal diagnosis and management. Without disorder-appropriate treatment, affected individuals potentially face life-threatening bleeding, delayed diagnosis, suboptimal management of invasive procedures, psychosocial distress, pain, and decreased quality-of-life.Research design and methodsThe National Hemophilia Foundation (NHF) and the American Thrombosis and Hemostasis Network identified the priorities of people with inherited BDs and their caregivers, through extensive inclusive community consultations, to inform a blueprint for future decades of research. Multidisciplinary expert Working Group (WG) 3 distilled highly feasible transformative ultra-rare inherited BD research opportunities from the community-identified priorities.ResultsWG3 identified three focus areas with the potential to advance the needs of all people with ultra-rare inherited BDs and scored the feasibility, impact, and risk of priority initiatives, including 13 in systems biology and mechanistic science; 2 in clinical research, data collection, and research infrastructure; and 5 in the regulatory process for novel therapeutics and required data collection.ConclusionsCentralization and expansion of expertise and resources, flexible innovative research and regulatory approaches, and inclusion of all people with ultra-rare inherited BDs and their health care professionals will be essential to capitalize on the opportunities outlined herein.